Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026

CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.

View Full Paper
Ask AI
Bookmark
Share

Authors

FEFatma ElsayedJBJ BabanHEHeba yahia Elkholy

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis show CAR-T therapy improves survival in R/R DLBCL, suggesting favorable outcomes.

Key Points

  • This review aims to compare the effectiveness of CAR-T therapy with salvage chemotherapy for relapsed/refractory DLBCL.
  • Conducted a systematic review and meta-analysis following PRISMA 2020 and MOOSE guidelines.
  • Included randomized controlled trials and high-quality comparative cohort studies with adult patients diagnosed with R/R DLBCL.
  • Analyzed primary outcomes: overall survival (OS) and progression-free survival (PFS); secondary outcomes included complete metabolic response and toxicity profiles.
  • CAR-T therapy significantly improved PFS (HR 0.55, 95% CI 0.42-0.71; p < 0.001) and OS (HR 0.68, 95% CI 0.54-0.86; p = 0.001).
  • CMR rates were higher in the CAR-T group (56.0%) compared to salvage chemotherapy (24.5%) (RR 2.28, 95% CI 1.82-2.86; p < 0.001).
  • CAR-T therapy was associated with cytokine release syndrome (9% grade ≥3) and ICANS (12%); salvage chemotherapy had higher rates of hematologic toxicity.

Cite This Study

Elsayed et al. (2026) studied this question.

synapsesocial.com/papers/6a3f69caaea7db3c195407c5https://doi.org/10.7417/ct.2026.2084
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recent trends in the management of relapsing/refractory diffuse large B-cell lymphoma: A systematic review of the literature2025
  2. 2Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis2025
  3. 3Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2025
  4. 4Efficacy and safety of chimeric antigen receptor (CAR) T-cell therapy in richter transformation: A systematic review and meta-analysis2025
  5. 5CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations